

Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party — that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether

earning royalties or not

Royalties: Funds are coming in to you or your institution due to your

Saunte 1

patent



Saunte

ICMJE Form for Disclosure of Potential Conflicts of Interest

1 Given Name (France)			
1. Given Name (First Name) Ditte Marie Lindhardt	2. Surname (Last Name) Saunte		3. Date 10-February-2019
4. Are you the corresponding author?	Yes No	Corresponding Au Pernille Lindsø A	thor's Name
i. Manuscript Title Tinea capitis - en overset sygdom hos	børn		inderself.
i. Manuscript Identifying Number (if you k JFL-06-19-0332	(now it)		
Section 2. The Week Under			
id you or your institution at any time received aspect of the submitted work (including	onsideration for Publi		
ny aspect of the submitted work (including atistical analysis, etc.)? re there any relevant conflicts of inter	est? Yes No		
Relevant financial	activities outside the s	88 S S	cial relationships (regardless of amo
lace a check in the appropriate boxes if compensation) with entities as descricking the "Add +" box. You should repart there any relevant conflicts of interest.	in the table to indicate whe ibed in the instructions. Us port relationships that were est?	ether you have finan	cial relationships (regardless of amo ntity; add as many lines as you need e 36 months prior to publication .
Relevant financial ace a check in the appropriate boxes in the appropriate boxes in compensation) with entities as described in the "Add +" box. You should report there any relevant conflicts of interested, please fill out the appropriate info	in the table to indicate when the instructions. Us boort relationships that were st? Yes No ormation below.	ether you have finan e one line for each e e present during th	cial relationships (regardless of amo ntity; add as many lines as you need e 36 months prior to publication .
Relevant financial ace a check in the appropriate boxes is compensation) with entities as descricking the "Add +" box. You should repet there any relevant conflicts of interexes, please fill out the appropriate informe of Entity	in the table to indicate who ibed in the instructions. Us port relationships that were est? Yes No ormation below.	ether you have finan	cial relationships (regardless of amo ntity; add as many lines as you need e 36 months prior to publication. Comments
Relevant financial ace a check in the appropriate boxes i compensation) with entities as descri cking the "Add +" box. You should rep e there any relevant conflicts of intere yes, please fill out the appropriate info	in the table to indicate who ibed in the instructions. Us port relationships that were est? Yes No ormation below.	ether you have finan e one line for each e e present during th -Financial Other	ntity; add as many lines as you need e 36 months prior to publication.
Relevant financial ace a check in the appropriate boxes i compensation) with entities as descri cking the "Add +" box. You should rep e there any relevant conflicts of intere res, please fill out the appropriate info me of Entity ee	in the table to indicate when the districtions. Use the control of	ether you have finan e one line for each e e present during th -Financial Other	e 36 months prior to publication. Comments
Relevant financial ace a check in the appropriate boxes i compensation) with entities as descri cking the "Add +" box. You should rep e there any relevant conflicts of intere res, please fill out the appropriate info me of Entity ee	in the table to indicate when the dibed in the instructions. Us port relationships that were est? Yes No primation below. Grant? Personal Non Fees? Su	ether you have finan e one line for each e e present during th -Financial Other	e 36 months prior to publication. Comments Advisory board
Relevant financial ace a check in the appropriate boxes is compensation) with entities as described the "Add +" box. You should regard there any relevant conflicts of interestes, please fill out the appropriate informe of Entity e	in the table to indicate when the districtions. Use the districtions in the instructions. Use the distriction in the instructions. Use the distriction in the instructions. Use the distriction in the instruction in the instructions. Use the instruction in the i	ether you have finan e one line for each e e present during th -Financial Other	e 36 months prior to publication. Comments Advisory board Advisory board
Relevant financial ace a check in the appropriate boxes i compensation) with entities as descri cking the "Add +" box. You should rep e there any relevant conflicts of intere yes, please fill out the appropriate info me of Entity ie	in the table to indicate who ibed in the instructions. Us cort relationships that were est? Yes No ormation below. Grant	ether you have finance one line for each e present during the present	e 36 months prior to publication. Comments Advisory board Advisory board Advisory board Speakers honory
Relevant financial lace a check in the appropriate boxes if compensation) with entities as descricking the "Add +" box. You should represent there any relevant conflicts of interespes, please fill out the appropriate informe of Entity rie en fi ie	in the table to indicate whe libed in the instructions. Us cort relationships that were est?	ether you have finance one line for each end end in effect end of the present during the end of the present during the end of the en	e 36 months prior to publication. Comments Advisory board Advisory board Advisory board Speakers honory Speakers honory
Relevant financial Place a check in the appropriate boxes in from pensation) with entities as describlicking the "Add +" box. You should report there any relevant conflicts of interest yes, please fill out the appropriate information of the sen of the s	n the table to indicate who ibed in the instructions. Us cort relationships that were est? Yes No ormation below. Grant Personal Non Fees Su Y Y Y Y Y Y Y Y Y	ether you have finance one line for each ele present during the operation of the operation	e 36 months prior to publication. Comments Advisory board Advisory board Advisory board Speakers honory



Name of Entity		Grant Persona	Non-Financial	Other?	Comments	
Sanofi			✓ ✓		Congress fee and	accomondation
Jannsen			V		Congress fee and	
Section 4.	Intellectual Prope		- Marie Commission of the Comm	ant to the	work? Yes	√ No
Section 5.	Relationships not		ica, broudy releva	ant to the v	WOIK: TES	V NO
potentially influe	elationships or activiti encing, what you wrote wing relationships/cor	e in the submitted w	ork?		WE	e appearance of
At the time of ma	tionships/conditions/o anuscript acceptance, rnals may ask authors	journals will ask auth	nors to confirm an	d, if necess	ary, update the	ir disclosure statements.
Section 6.	Disclosure Statem					
Based on the abo below.	ove disclosures, this fo	rm will automatically	generate a disclo	osure statei	ment, which wil	I appear in the box
Abbvie, persona	rts personal fees from a I fees from Galderma, n-financial support fro	personal fees from A	stellas, personal fe	ees from Le	eo Pharma, non-	financial support



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether

earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

Arendrup 1



Section 1. Identifying Inform	mation			
1. Given Name (First Name) Maiken Cavling	2. Surname (Last Name) Arendrup		3. Date 04-October-2019	
4. Are you the corresponding author?	☐ Yes ✓ No	Corresponding A		
5. Manuscript Title Tinea capitis - en overset sygdom hos	børn			
6. Manuscript Identifying Number (if you k UFL-06-19-0332	know it)			
		_		
Section 2. The Work Under C	Consideration for Public	cation		
Did you or your institution at any time recanny aspect of the submitted work (includin statistical analysis, etc.)? Are there any relevant conflicts of interesting the statistical analysis.	g but not limited to grants, da		ernment, commercial, private foundation, etc.) rd, study design, manuscript preparation,	for
Section 3. Relevant financial	l activities outside the s	submitted wor	k	
Place a check in the appropriate boxes of compensation) with entities as desc	in the table to indicate where in the instructions. Useport relationships that we rest?	ether you have fi se one line for ea	nancial relationships (regardless of amour ch entity; add as many lines as you need b g the 36 months prior to publication.	
Name of Entity	Grant? Personal No	n-Financial Support?	er? Comments	
Astellas, Basilea, Gilead, MSD, Pfizer			Sppeakers honoraria	
Amplyx, Basilea, Cidara, F2G, Gilead, Novabiotics, Pfizer, Scynexis & T2Candida			Paiment for contract work, paid to the Statens Serum Institute	
Section 4. Intellectual Prope Do you have any patents, whether plan	erty Patents & Copyrio		the work? Yes 🗸 No	
Do you have any patents, whether plan	nned, pending or issued, br	oadly relevant to	the work! Yes V No	

Arendrup 2



Section 5. Polationships not severed above
Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Arendrup reports personal fees from Astellas, Basilea, Gilead, MSD, Pfizer, grants from Amplyx, Basilea, Cidara, F2G, Gilead, Novabiotics, Pfizer, Scynexis & T2Candida, outside the submitted work;.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Arendrup 3



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued

Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent



Section 1. Identifying Informa	ation			
1. Given Name (First Name) Gregor	2. Surname (Last N Jemec	ame)	3. Date 06-September-20	19
4. Are you the corresponding author?	☐ Yes ✓ No	-	ding Author's Name ndsø Andersen	
5. Manuscript Title Tinea capitis - en overset sygdom hos bø	ørn			
6. Manuscript Identifying Number (if you kno UFL-06-19-0332	ow it)			
Section 2. The Work Under Co				
The Work Under Co	nsideration for	Publication		
Did you or your institution at any time received any aspect of the submitted work (including statistical analysis, etc.)? Are there any relevant conflicts of interest	but not limited to gr			
Section 3. Relevant financial a	ctivities outside	the submitted	work.	
Place a check in the appropriate boxes in of compensation) with entities as described clicking the "Add +" box. You should repart there any relevant conflicts of interesting the please fill out the appropriate information.	oed in the instruction ort relationships the st? Yes	ons. Use one line f	or each entity; add as many lines as	s you need by
Name of Entity	Grant? Persona	I Non-Financial Support?	Other? Comments	
Abbvie	✓		trial	
Abbvie			adboard	
Coloplast			adboard	
InflRx	✓		trial	
Incytes			adboard	
Janssen Pharma	✓		trial	
Novartis			adboard & speaker	
Novartis	✓		trial	



Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments	
Regeneron	✓				trial	
Sanofi	✓				trial	
UCB		\checkmark			adboard	
Section 4. Intellectual Property						
Intellectual Property Patents & Copyrights						
Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes Vo						
Section 5. Relationships not o	overed	above				
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?						
Yes, the following relationships/conditions/circumstances are present (explain below):						
✓ No other relationships/conditions/circumstances that present a potential conflict of interest						
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statement On occasion, journals may ask authors to disclose further information about reported relationships.					nents.	
Section 6. Disclosure Stateme	nt					
Based on the above disclosures, this forn below.		omatically (generate a disclos	sure state	ment, which will appear in the box	
Dr. Jemec reports grants from Abbvie, p fees from Incytes, grants from Janssen P grants from Sanofi, personal fees from U	harma, pe	ersonal fee	s from Novartis, g			



Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

licensed. The patent has been licensed to an entity

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

Lindsø Andersen 1



Section 1. Identifying Infor	mation					
1. Given Name (First Name) Pernille	2. Surname (Last Name) Lindsø Andersen	3. Date 07-October-2019				
4. Are you the corresponding author?	ou the corresponding author? Yes No					
5. Manuscript Title Tinea capitis - en overset sygdom hos	børn					
6. Manuscript Identifying Number (if you UFL-06-19-0332	know it)					
Section 2. The Work Under	Consideration for Publication					
any aspect of the submitted work (including statistical analysis, etc.)? Are there any relevant conflicts of inte	ng but not limited to grants, data monitorii	y (government, commercial, private foundation, etc.) for ng board, study design, manuscript preparation,				
Section 3. Relevant financia	l activities outside the submitted	l work.				
of compensation) with entities as desc	eribed in the instructions. Use one line eport relationships that were present erest? Yes No	nave financial relationships (regardless of amount for each entity; add as many lines as you need by during the 36 months prior to publication.				
Name of Entity	Grant? Personal Non-Financia Fees? Support?	Other? Comments				
EO Pharma	✓	PhD grant (grant no.: LF 18002)				
Section 4. Intellectual Prope	erty Patents & Copyrights					
Do you have any patents, whether pla	nned, pending or issued, broadly relev	vant to the work? ☐ Yes ✓ No				

Lindsø Andersen 2



Section 5. Relationships not sovered above
Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
✓ No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Lindsø Andersen reports grants from LEO Pharma, outside the submitted work; .

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Lindsø Andersen 3